Episode Summary
Executive Summary: Erin Welsh interviews journalist Robert Kolker about The Vanishing Family, tracing a multigenerational family afflicted by inherited frontotemporal dementia (FTD). The conversation explains FTD’s personality-changing symptoms, genetic inheritance, diagnosis challenges, caregiver burden, and how new tau-targeting treatments may reshape research and hope.
Main Topics: The Vanishing Family and inherited FTD (Priority: 5/5): Colker explains how he came to write about a nine-sibling family whose mother and later multiple children showed signs of frontotemporal dementia, revealing the disease’s devastating family impact. What FTD is and why it is so hard to recognize (Priority: 5/5): The discussion emphasizes that FTD often presents as behavioral and personality change rather than memory loss, making it easy to misread as depression, alcoholism, or bad behavior. Genetics, testing, and the burden of knowing (Priority: 5/5): A major theme is the 50/50 autosomal dominant inheritance pattern in some FTD families and the emotional consequences of choosing whether to learn one’s genetic status. History of dementia science and public perception (Priority: 4/5): Welsh and Colker discuss how dementia was historically understood, how Alzheimer’s came to dominate the field, and how FTD and other dementias were long overlooked in research and diagnosis. Caregiving and family dynamics (Priority: 4/5): The interview explores how relatives—especially sisters and spouses—become long-term caregivers, managing grief, logistics, and emotional compartmentalization over years or decades. Scientific hope and future treatments (Priority: 4/5): Colker points to optimism around tau-focused drugs and broader precision-medicine approaches that may eventually treat dementia earlier, possibly even preventively.
Key Arguments: FTD is especially cruel because it can alter personality before memory, so families often misinterpret symptoms as moral or psychological problems rather than neurodegeneration. Inherited FTD can be tested genetically, creating a 'crystal ball' dilemma: knowing one’s future can be psychologically devastating, but not knowing can also be torturous. The disease is underdiagnosed because clinicians and families often do not suspect dementia when a person becomes apathetic, impulsive, reckless, or emotionally disconnected. Dementia research has been distorted by Alzheimer’s dominance; rarer conditions like FTD were historically lumped into 'senility' or Alzheimer's, slowing progress and muddying studies. Caregivers often survive by compartmentalizing grief and focusing on immediate tasks rather than constant emotional collapse. Recent tau-focused drug development offers cautious optimism, especially for MAPT-related FTD, though the field is still early and many mechanisms remain unclear.
Data Points: Family size: 9 siblings - The family at the center of The Vanishing Family consists of nine siblings facing inherited FTD risk. Inheritance risk: 50-50 chance - Colker describes inherited FTD in this family as autosomal dominant, giving each child a coin-flip risk. Age of onset: Middle age / 40s to 50s - FTD often appears in midlife, unlike many dementias that arise later. Jean’s death: In her 50s - The family matriarch, Jean, died in 1990 after years of unexplained behavioral change. Diagnosis timeline: 2008 confirmed genetic mutation - The family’s mutation was confirmed in 2008, though science knew of it as early as 1998. Gap between discovery and confirmation: 10 years - Colker stresses the delay between identifying the mutation and the family receiving a confirmed diagnosis. Estimated FTD prevalence: 60,000 counted; possibly double - Colker says FTD is likely undercounted because it is difficult to diagnose and often overlooked. Alzheimer’s share of dementia: About 60% - He notes that Alzheimer’s may account for only around 60% of dementia cases, not all of them. Harvard display: 4 studies - He says at least four studies have tried to infer the exact path of the iron rod through Phineas Gage’s skull. Drug trial result: Phase 2 positive - He mentions encouraging phase-two results for a Biogen tau-reducing drug discussed at a major dementia conference.
Pivotal Quotes: "Dementia, in all its forms, is a disease of erasure." — Erin Welsh: Opening framing of the episode’s emotional and scientific focus. "They know exactly what this mutation is." — Robert Colker: He explains why this family’s case felt different from his prior book on schizophrenia and why gene editing seemed imaginable. "What astonished me about FTD is that when it happens in an inherited way with families, you have people who are watching the people they love most in their life change completely." — Robert Colker: Colker describes the emotional shock of watching personality change in relatives who are still physically alive and functional.
Implications: The episode underscores that dementia is not one disease but many, and that earlier genetic testing, better diagnostics, and tau-focused therapies could transform care. It also highlights the human cost of uncertainty for families and caregivers.